Abstract:Although the mortality rate in breast cancer (BC) has been reduced by the advancing technology, the outcome of patients with “triple-negative” (TN) BC (accounts for 10-17% of invasive BC) has achieved little progression. Recently, inhibitors of poly (adenosine-disposphate-ribose) polymerase (PARP) have been developed to target cells with defective DNA repair molecules such as BRCA1-deficient cells. Despite the tumor regression induced by these agents in a subset of BCs, their ability to effect patient outcome remains inconclusive. According to the CSC hypothesis, a hierarchical tumor organization exists whereby dysregulated self-renewing CSCs drive tumorigenesis. Our preliminary results showed that PARP inhibitor significantly decreased cell number in BRCA1-deficient SUM149 cells in a dose-dependent manner, whereas BRCA1 wild type SUM159 cells were relatively resistant. However, there was little change in absolute CSC number in SUM149 cells after PARP inhibitor treatment, suggesting PARP inhibitor only targets the non-CSC population in SUM149 cells. More interestingly, the resistant population expressed higher active Rad51 as measured for Rad51 foci formation. Our pervious study also showed that Rad51 mRNA level was significantly higher in ALDH+ cells of some breast cancer cell lines. Therefore, in this study, we established an inducible knock-down system using lentivirus and found that knocking down Rad51 sensitizes SUM159 (both CSC and non-CSC) as well as ALDH+ SUM149 cells to PARP inhibitor, suggesting the expression of Rad51 is associated with PARP inhibitor resistant population. This system was also tested in mouse model where cells carrying Rad51 shRNA were injected into the mammary fat pads of female NOD/SCID mice. Knock-down of Rad51 alone and combination treatment with PARP inhibitor dramatically inhibited tumor growth in the xenografts of both SUM149 and SUM159 cells, whereas, tumor grew back after Rad51 expression was restored. However the inhibitory effect remained in the combined treatment group after the treatment was terminated. Furthermore, the combination treatment decreased ALDH+ cells by IHC staining. It also showed a significant decrease in tumor-initiating cells in the combined treatment group by limiting dilution transplantation. Our results suggest that Rad51 plays an important role in resistance to PARP inhibitor in TNBCSCs thus Rad51 inhibitor may be a novel therapeutic approach in addition to PARP inhibition for treating TNBC patients. Citation Format: Yajing Liu, Rachel Martin, Shoumin Bai, Max Wicha, Suling Liu. Rad51 is involved in PARP inhibitor resistance in triple-negative breast cancer stem cells (TNBCSCs). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3720. doi:10.1158/1538-7445.AM2013-3720

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figures from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure Legends from Mir-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer

Supplementary Figure Legends from DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair

Supplementary Figure Legends 1-5 from Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Rad51 Is Involved In Parp Inhibitor Resistance In Triple-Negative Breast Cancer Stem Cells (Tnbcscs).

Supplementary Figure Legends from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate